The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (ABSI) (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to ...
HC Wainwright reiterated their buy rating on shares of Absci (NASDAQ:ABSI – Free Report) in a research report report published on Wednesday,Benzinga reports. They currently have a $7.00 price target ...
Absci (NASDAQ:ABSI – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Guggenheim in a research note issued to investors on Thursday,Benzinga reports. They presently have ...
VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results